This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

ACT NOW Longitudinal Study: Outcomes of Babies With Opioid Exposure Study

Sponsored by Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program

About this trial

Last updated 2 years ago

Study ID

ACTNOW-03

Status

Recruiting

Type

Observational

Placebo

No

Accepting

18-75 Years
Up to 1 Years
All
All

Trial Timing

Ended 2 years ago

What is this trial about?

The objective of this longitudinal cohort study is to quantify the effects of antenatal opioid exposure on the trajectory of brain development over the first 2 years of life, examine associations with developmental and neurobehavioral outcomes, and explore how specific factors (differing antenatal and postnatal exposures, severity of neonatal opioid withdrawal, maternal stress/depression/parenting) modify these effects

What are the participation requirements?

Yes

Inclusion Criteria

- Exposed infants: Born ≥37 weeks gestation with second or third trimester opioid exposure

- Control infants: Born ≥37 weeks gestation with no antenatal drug exposure

No

Exclusion Criteria

1. Infants with known chromosomal or congenital anomalies potentially affecting the central nervous system

2. Apgar score at 5 minutes of <5

3. Any requirement for positive pressure ventilation in the NICU

4. Inability to return for outpatient MRI and/or follow-up

5. IUGR <3rd percentile

6. Heavy alcohol use during pregnancy (8+ drinks per week).

Locations

Location

Status

Recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting